Safety Study of X-82 in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.

Phase 1

Tyrogenex